PharmCAT.NET

Biostatistics, pharmacokinetics and clinical trials.

  • Home page
  • Blog
  • Contacts
  • Agreement & Confidentiality

IBM SPSS Extension: R Project PowerTOST library

Posted on December 31, 2018December 31, 2018 by frozencat

IBM SPSS Extension PowerTOST R Project library. Syntax command: POWERTOST.

Version: 1.0.0

Functions:

  • power.TOST
  • sampleN.TOST
  • CVfromCI

Дизайны:

  • parallel
  • 2×2
  • 2x2x4

Скачать/Download

GitHUB: https://github.com/PharmCat/SPSSPowerTOST

Categories: Blog, SPSS

Post navigation

Next Post:

Recent Posts

  • IBM SPSS + R Project: Confidence intervals for proportions, independent groups
  • IBM SPSS Extension: R Project PowerTOST library

Галерея

20170730 173527
20180813 224437
20170730 175904
20170804 152706
IMG-20170807-WA0009
IMG-20170807-WA0016
  • FDA Takes Steps to Advance the Development of Novel Therapies for Stimulant Use Disorders
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-10-04 By FDA
  • Human medicines European public assessment report (EPAR): Zarzio, filgrastim, Neutropenia;Hematopoietic Stem Cell Transplantation;Cancer, Date of authorisation: 06/02/2009, Revision: 24, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
  • Stimulant Use Disorders: Developing Drugs for Treatment
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-10-04 By FDA
  • CDER Takes Measures to Tackle Stimulant Use Disorder
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-10-04 By FDA
  • Newly Added Guidance Documents
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-10-04 By FDA
  • Human medicines European public assessment report (EPAR): Adrovance, alendronic acid,colecalciferol, Osteoporosis, Postmenopausal, Date of authorisation: 04/01/2007, Revision: 25, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
  • Human medicines European public assessment report (EPAR): Trixeo Aerosphere, formoterol,glycopyrronium bromide,budesonide, Pulmonary Disease, Chronic Obstructive, Date of authorisation: 09/12/2020, Revision: 4, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
  • Human medicines European public assessment report (EPAR): Ovitrelle, choriogonadotropin alfa, Anovulation;Reproductive Techniques, Assisted;Infertility, Female, Date of authorisation: 02/02/2001, Revision: 22, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
  • Human medicines European public assessment report (EPAR): Filgrastim Hexal, filgrastim, Neutropenia;Hematopoietic Stem Cell Transplantation;Cancer, Date of authorisation: 06/02/2009, Revision: 23, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
  • Human medicines European public assessment report (EPAR): CellCept, mycophenolate mofetil, Graft Rejection, Date of authorisation: 14/02/1996, Revision: 38, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
  • Human medicines European public assessment report (EPAR): Lixiana, edoxaban, Stroke;Venous Thromboembolism, Date of authorisation: 19/06/2015, Revision: 18, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
  • Human medicines European public assessment report (EPAR): Riltrava Aerosphere, formoterol fumarate dihydrate,glycopyrronium,budesonide, Pulmonary Disease, Chronic Obstructive, Date of authorisation: 06/01/2022, Revision: 2, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
  • Human medicines European public assessment report (EPAR): Roteas, edoxaban, Stroke;Venous Thromboembolism, Date of authorisation: 19/04/2017, Revision: 11, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
  • Biological Products - Specific Labeling Resources
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-10-03 By FDA
  • GDUFA Type II API DMF Payment Receipts Report
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-10-03 By FDA
Older posts
Theme: Scaffold by Danny Cooper.